Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma
- PMID: 15964184
- DOI: 10.1016/j.ejca.2005.04.019
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma
Abstract
The expression of cyclooxygenase 2 (COX-2) protein is increased in many tumours and may be associated with a more aggressive phenotype. We aimed to assess COX-2 expression in a large series of archival mesothelioma specimens. Archival tissue was obtained from 86 malignant pleural mesothelioma samples (histological subtype: 42 epithelial, 28 biphasic and 16 sarcomatoid). Overexpression of COX-2 was detected by immunohistochemical analysis. Positive staining was located in the cytoplasm of malignant tumour cells. Overall 51/86 (59%) tumour sections demonstrated COX-2 overexpression. The frequency varied with histological subtype with 31/42 (73%) of epithelial sections, 14/28 (50%) of biphasic sections and 6/16 (37%) of sarcomatoid sections recorded as positive. Kaplan Meier survival analysis indicated that overexpression of COX-2 was significantly related to improved prognosis (P < 0.001) and was an independent prognostic factor in multivariant analysis. Overexpression of COX-2 protein may confer a survival advantage in mesothelioma patients.
Similar articles
-
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.Clin Cancer Res. 2002 Jun;8(6):1857-62. Clin Cancer Res. 2002. PMID: 12060628
-
Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.Oncol Rep. 2005 Aug;14(2):357-62. Oncol Rep. 2005. PMID: 16012715
-
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.Lung Cancer. 2006 Dec;54(3):399-407. doi: 10.1016/j.lungcan.2006.08.012. Epub 2006 Oct 17. Lung Cancer. 2006. PMID: 17049671
-
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.Lung Cancer. 2004 Aug;45 Suppl 1:S45-8. doi: 10.1016/j.lungcan.2004.04.025. Lung Cancer. 2004. PMID: 15261433 Review.
-
Prognostic markers in malignant mesothelioma.Adv Clin Path. 2000 Oct;4(4):185-6. Adv Clin Path. 2000. PMID: 11436154 Review. No abstract available.
Cited by
-
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.BMJ Open Respir Res. 2018 Jan 30;5(1):e000240. doi: 10.1136/bmjresp-2017-000240. eCollection 2018. BMJ Open Respir Res. 2018. PMID: 29468073 Free PMC article.
-
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.Mol Cancer Ther. 2009 Sep;8(9):2575-85. doi: 10.1158/1535-7163.MCT-09-0390. Epub 2009 Sep 15. Mol Cancer Ther. 2009. PMID: 19755515 Free PMC article.
-
PTEN protein expression in malignant pleural mesothelioma.Tumour Biol. 2013 Apr;34(2):847-51. doi: 10.1007/s13277-012-0615-9. Epub 2012 Dec 15. Tumour Biol. 2013. PMID: 23242608
-
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.Cancers (Basel). 2010 Apr 14;2(2):523-48. doi: 10.3390/cancers2020523. Cancers (Basel). 2010. PMID: 24281081 Free PMC article.
-
Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.J Transl Med. 2008 May 22;6:27. doi: 10.1186/1479-5876-6-27. J Transl Med. 2008. Retraction in: J Transl Med. 2022 Dec 27;20(1):624. doi: 10.1186/s12967-022-03834-5. PMID: 18498639 Free PMC article. Retracted.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials